<DOC>
	<DOCNO>NCT02816580</DOCNO>
	<brief_summary>Epidemiological data Europe show around 30 % subject age 65 year age pre-frail , 15 % frail . Recent research demonstrate identify frailty implement preventive measure help slow cognitive decline . Screening treat frailty seem good start towards prevent dependency . On premise frailty result pronounce tissue alteration certain elderly subject , assessment post-translational modification derive product ( PTMDP ) represent innovative evaluation method . These include advanced glycation end-products ( AGE ) , carbamylation-derived product ( homocitrulline ) . Indeed , intensity modification increase age , assess product result alteration could show existence difference accord frailty status . This would make possible adapt treatment accordingly elderly subject .</brief_summary>
	<brief_title>Biological MArkers FRAilty Elderly Subjects</brief_title>
	<detailed_description />
	<criteria>With social security coverage Accept participate study sign inform consent study collection biological sample &lt; 65 yo</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>